Ruboxistaurin for the treatment of diabetic peripheral neuropathy: A systematic review of randomized clinical trials

Diabetes and Metabolism Journal

Volumn 37, Issue 5, 2013, Pages 375-384

  Bansal, Dipika ^a   Badhan, Yogesh ^a   Gudala, Kapil ^a   Schifano, Fabrizio ^b  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Diabetic peripheral neuropathy; Protein kinase C inhibitor; Ruboxistaurin

Indexed keywords

PLACEBO; RUBOXISTAURIN;

ARTICLE; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; NEUROLOGIC EXAMINATION; NEUROLOGICAL TOTAL SYMPTOM SCORE; OUTCOME ASSESSMENT; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SIDE EFFECT; SKIN BLOOD FLOW; SYSTEMATIC REVIEW; VIBRATION DETECTION THRESHOLD;

EID: 84887163693     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2013.37.5.375     Document Type: Article

References (31)

1. Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia 1998;41:1263-9.
2. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ 3rd, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24.
3. Kumar S, Ashe HA, Parnell LN, Fernando DJ, Tsigos C, Young RJ, Ward JD, Boulton AJ. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med 1994;11:480-4.
4. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-4.
5. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998;15:508-14.
6. Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993;16:1446-52.
7. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008;120:1-34.
8. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-62.
9. Masson EA, Boulton AJ. Aldose reductase inhibitors in the treatment of diabetic neuropathy: a review of the rationale and clinical evidence. Drugs 1990;39:190-202.
10. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001;107:1215-8.
11. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007;(4):CD004572.
12. Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008;28:646-55.
13. Ring BJ, Gillespie JS, Binkley SN, Campanale KM, Wrighton SA. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos 2002;30:957-61.
14. Burkey JL, Campanale KM, Barbuch R, O'Bannon D, Rash J, Benson C, Small D. Disposition of [14C]ruboxistaurin in humans. Drug Metab Dispos 2006;34:1909-17.
15. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
16. Bastyr EJ 3rd, Price KL, Bril V; MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 2005;27:1278-94.
17. Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd; MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005;27:1164-80.
18. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999;41 Suppl 1:8-13.
19. Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ 3rd, Wolka AM, Vinik AI. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007;30:896-902.
20. Boyd A, Casselini C, Vinik E, Vinik A. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol 2011;5:714-22.
21. Casellini CM, Barlow PM, Rice AL, Casey ME, Simmons K, Pittenger G, Bastyr E, Vinik A. Effect of ruboxistaurin (RBX) on quantitative measures of diabetic peripheral neuropathy (DPN). 66th Scientific Session 2006; June 9-13; Washington, DC. Alexandria: American Diabetes Association; 2006.
22. Casellini CM, Barlow PM, Rice AL, Vinik AA. Effect of ruboxistaurin (RBX) on skin microvascular blood flow (SBF), sensory symptoms, and sensory perception in patients with diabetic peripheral neuropathy (DPN). 66th Scientific Session 2006; June 9-13; Washington, DC. Alexandria: American Diabetes Association; 2006.
23. Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. J Diabetes Complications 2008;22:88-95.
24. Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL; Ruboxistaurin Study Group. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care 2007;30:2626-32.
25. Craven PA, Davidson CM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990;39:667-74.
26. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997;81:363-71.
27. Kishimoto A, Takai Y, Mori T, Kikkawa U, Nishizuka Y. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 1980;255:2273-6.
28. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-9.
29. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008;9:14-36.
30. European Medicines Agency: Withdrawal assessment report for arxxant: Ruboxistaurin (as mesilate monohydrate). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdf (updated 2007 May 24).
31. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450-9.